Pinnacle Wealth Planning Services Inc. Sells 12,034 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Pinnacle Wealth Planning Services Inc. cut its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 48.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,710 shares of the biotechnology company’s stock after selling 12,034 shares during the quarter. Pinnacle Wealth Planning Services Inc.’s holdings in BioCryst Pharmaceuticals were worth $96,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Counterweight Ventures LLC increased its holdings in shares of BioCryst Pharmaceuticals by 591.7% in the 3rd quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock valued at $710,000 after acquiring an additional 79,884 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of BioCryst Pharmaceuticals by 40.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock valued at $2,274,000 after acquiring an additional 86,571 shares during the period. Principal Financial Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 1,058.1% in the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after acquiring an additional 375,890 shares during the period. Fisher Asset Management LLC grew its stake in BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after buying an additional 481,359 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in BioCryst Pharmaceuticals by 5.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,887,994 shares of the biotechnology company’s stock worth $14,349,000 after buying an additional 102,860 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on BCRX. JMP Securities restated a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Needham & Company LLC boosted their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and set a $11.00 target price (up from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Finally, Evercore ISI boosted their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $7.69 on Friday. The stock has a 50-day moving average of $8.15 and a two-hundred day moving average of $7.87. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $9.50. The stock has a market cap of $1.61 billion, a P/E ratio of -12.61 and a beta of 1.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. During the same period in the prior year, the company posted $0.28 earnings per share. The business’s revenue for the quarter was up 40.8% compared to the same quarter last year. Analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.